Alveolar-Bone
发表于 2025-3-26 22:07:36
Prognostic Factors at Initial Presentation and in Recurrent Diseases well as to compare treatment results across different institutions. The issue of prognostic factors can be divided into two broad categories. One focuses on the use of prognostic factors in clinical stage I seminoma and non-seminoma in order to assess a patient’s risk of having occult metastatic d
广大
发表于 2025-3-27 03:48:43
http://reply.papertrans.cn/28/2706/270582/270582_32.png
hyperuricemia
发表于 2025-3-27 07:59:28
What Are the Recent Recommendations for Follow-Up in Testicular Cancer?(adjuvant therapy or curative treatment of advanced disease), is an important part of the management of this disease. The primary aim of follow-up is the timely diagnosis of recurrent disease in order to be able to treat the patient with curative intent with the least aggressive therapy . An adeq
狂热文化
发表于 2025-3-27 13:03:18
http://reply.papertrans.cn/28/2706/270582/270582_34.png
AGOG
发表于 2025-3-27 15:30:31
Consequences of the Disease and Its Treatment Concerning Sexuality and Fertilitypart from late toxicity affecting general health by either vascular, neuropathic, nephrotoxic or ototoxic side effects or by inducing second malignancies, fertility and sexuality are negatively affected. Gonadal function is essential for fertility and normal endocrine profile. Both the disease itsel
Entirety
发表于 2025-3-27 18:54:43
http://reply.papertrans.cn/28/2706/270582/270582_36.png
不妥协
发表于 2025-3-27 22:30:22
http://image.papertrans.cn/d/image/270582.jpg
LINES
发表于 2025-3-28 05:17:24
http://reply.papertrans.cn/28/2706/270582/270582_38.png
FORGO
发表于 2025-3-28 07:46:36
978-3-319-35963-2Springer International Publishing Switzerland 2015
MOAT
发表于 2025-3-28 10:58:52
Is There Still an Indication for Radiotherapy in Seminoma Clinical Stages I–IIA/B?ed second cancer. Adjuvant chemotherapy with carboplatin or active surveillance represents effective alternative therapeutic options in stage I. For patients with limited stage II, radiotherapy may be considered though cisplatin-based chemotherapy is the treatment preferred by most European clinicians.